+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-07-25Number of Pages: 243

Ophthalmic Drugs Market (Disease Indication - Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders (Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, and Diabetic Retinopathy), Allergy, and Uveitis; Therapeutic Class - Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs and Anti-bacterial Drugs), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, and Combined Medication), Anti-allergy Drugs, and Anti-VEGF Agents; Product Type - Prescription Drugs and Over-the-Counter Drugs; Distribution Channel - Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Global Ophthalmic Drugs Market: Snapshot

The global ophthalmic drugs market is seeing increasing number of co-development agreements among keen players to come up with novel biological agents having lesser treatment durations, players in emerging markets trying to tap into the unmet medical needs, and generic manufacturers strengthening their distribution networks of cost-effective drugs in rural outposts of developing regions, having high proportion of visually challenged people. All this is serving to catalyze growth in the market.

Besides, increasing prevalence of intraocular eye disorders, namely cataract, glaucoma, age-related macular degeneration, diabetic retinopathy, etc., mainly in the elderly, is also stoking growth in the global ophthalmic market. The rising incidence of eye diseases, worldwide, such as dry eye, conjunctivitis, uveitis, and others, is also serving to boost the market. Astute companies in the world are already increasing allocations on investments in research to come up with more effective drugs formulated with novel biological agents.

A report by Transparency Market Research forecasts the global ophthalmic drugs market to rise at a lackluster CAGR of 4.0% between 2017 and 2025 to become worth US$34.3 bn by 2025 from US$24.4 bn in 2016.

ophthalmic drugs market

Spike in Patients Requiring Long-term Treatment Makes Retinal Disorders Dominant Segment

The global ophthalmic drugs market can be segmented based on disease indication into allergy, dry eye, glaucoma, retinal disorders, infection/inflammation, uveitis, etc. Of them, the retinal disorders segment, which can be further divided into wet age-related macular degeneration, dry age-related macular degeneration, and diabetic retinopathy, among others, leads the market with maximum share. This is mainly on account of the spike in number of patients seeking long-term treatment.

Going forward, however, the dry eye segment is predicted to clock maximum growth on the back of changing environmental conditions, ill-effects of increasing air pollution on eye, lined-up launches of innovative drugs with longer active action, and increased treatment penetration for dry eye.

Keen Players Attempting to Tap into Asia Pacific Market Buoy Growth

From a geographical standpoint, North America leads the global ophthalmic drugs market due to higher uptake of advanced novel products and techniques, and high cost of therapies in all regions. Rising at a CAGR of 4.0% from 2017 to 2025, the market is slated to become worth US$13.08 bn by 2025. Currently, the market in North America is seeing considerable changes on account of changing Medicare policies in the U.S., higher pricing of branded specialty drugs, and the rising patient pool for eye diseases.

Europe trails North America in terms of the size of the market. Numerous big names, actively involved in development of existing ophthalmic drugs to meet the ever-rising demands for the treatment of eye diseases such as cataract, glaucoma, and diabetic retinopathy, are the primary reason for the superior performance of the overall market in the region. Further, approval of new drugs by the European Union for treating eye disorders is also boosting the market in Europe.

Vis-à-vis growth rate, Asia Pacific is predicted to steal the show by registering a CAGR of 4.6% between 2017 and 2025. This is because numerous keen ophthalmology companies are charging into the relatively untapped markets in the region to grow their revenue and market share. China, India, and Malaysia are some of the most attractive markets in the regions on account of a substantial consumer base, rising healthcare spends, and patients’ inclination toward availing improved healthcare facilities.

Some of the key players operating in the global ophthalmic drugs market are ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ophthalmic Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Disease Indication Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
            4.4.4. Trends
     4.5. Global Ophthalmic Drugs Market Analysis and Forecasts, 2015–2025
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Porter’s Five Force Analysis
     4.7. Market Outlook
     4.8. Global Company Share Analysis: Glaucoma; 2016
     4.9. Pipeline Analysis: Major Market Players
     4.10. Pipeline Analysis: Emerging Market Players
     4.11. Comparison matrix for product offerings: Major Market Players
     4.12. Snapshot: Causes of blindness - Global
     4.13. Snapshot: Causes of blindness - Regional

5. Global Ophthalmic Drugs Market Analysis and Forecasts, By Disease Indication 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value Forecast by Disease Indication, 2015–2025
            5.4.1. Dry Eye
            5.4.2. Glaucoma
            5.4.3. Infection/Inflammation
            5.4.4. Retinal Disorders
                     5.4.4.1. Wet AMD
                     5.4.4.2. Dry AMD
                     5.4.4.3. Diabetic Retinopathy
                     5.4.4.4. Others
            5.4.5. Allergy
            5.4.6. Uveitis
            5.4.7. Others
     5.5. Market Attractiveness by Disease Indication 

6. Global Ophthalmic Drugs Market Analysis and Forecasts, By Therapeutic Class 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value Forecast By Therapeutic Class, 2015–2025
            6.4.1. Anti-inflammatory Drugs
                     6.4.1.1. NSAID
                     6.4.1.2. Steroids
            6.4.2. Anti-infective Drugs
                     6.4.2.1. Anti-fungal Drugs
                     6.4.2.2. Anti-bacterial Drugs
                     6.4.2.3. Others
            6.4.3. Anti-glaucoma Drugs
                     6.4.3.1. Alpha Agonist
                     6.4.3.2. Beta Blockers
                     6.4.3.3. Prostaglandin Analogs
                     6.4.3.4. Combined Medication
                     6.4.3.5. Others
            6.4.4. Anti-allergy Drugs
            6.4.5. Anti-VEGF Agents
            6.4.6. Others
     6.5. Market Attractiveness by Therapeutic Class 

7. Global Ophthalmic Drugs Market Analysis and Forecasts, By Product Type 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value Forecast by Product Type, 2015–2025
            7.4.1. Prescription Drugs
            7.4.2. OTC Drugs
     7.5. Market Attractiveness by Product Type 

8. Global Ophthalmic Drugs Market Analysis and Forecasts, By Distribution Channels 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Key Trends
     8.4. Market Value Forecast by Distribution Channels, 2015–2025
            8.4.1. Hospital Pharmacies
            8.4.2. Online Pharmacies
            8.4.3. Independent Pharmacies & Drug Stores
     8.5. Market Attractiveness by Distribution Channels 

9. Global Ophthalmic Drugs Market Analysis and Forecasts, By Region
     9.1. Key Findings
     9.2. Policies and Regulations
     9.3. Market Value Forecast by Region
            9.3.1. North America 
            9.3.2. Europe 
            9.3.3. Asia Pacific 
            9.3.4. Latin America 
            9.3.5. Middle East and Africa 
     9.4. Market Attractiveness by Country/Region

10. North America Ophthalmic Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
            10.1.3. Key Trends
     10.2. Market Value Forecast by Disease Indication, 2015–2025
            10.2.1. Dry Eye
            10.2.2. Glaucoma
            10.2.3. Infection/Inflammation
            10.2.4. Retinal Disorders
                     10.2.4.1. Wet AMD
                     10.2.4.2. Dry AMD
                     10.2.4.3. Diabetic Retinopathy
                     10.2.4.4. Others
            10.2.5. Allergy
            10.2.6. Uveitis
            10.2.7. Others
     10.3. Market Value Forecast by Therapeutic Class, 2015–2025
            10.3.1. Anti-inflammatory Drugs
                     10.3.1.1. NSAID
                     10.3.1.2. Steroids
            10.3.2. Anti-infective Drugs
                     10.3.2.1. Anti-fungal Drugs
                     10.3.2.2. Anti-bacterial Drugs
                     10.3.2.3. Others
            10.3.3. Anti-glaucoma Drugs
                     10.3.3.1. Alpha Agonist
                     10.3.3.2. Beta Blockers
                     10.3.3.3. Prostaglandin Analogs
                     10.3.3.4. Combined Medication
                     10.3.3.5. Others
            10.3.4. Anti-allergy Drugs
            10.3.5. Anti-VEGF Agents
            10.3.6. Others
     10.4. Market Value Forecast by Product Type, 2015–2025
            10.4.1. Prescription Drugs
            10.4.2. OTC Drugs
     10.5. Market Value Forecast by Distribution Channels, 2015–2025
            10.5.1. Hospital Pharmacies
            10.5.2. Online Pharmacies
            10.5.3. Independent Pharmacies & Drug Stores
     10.6. Market Value Forecast by Country, 2015–2025
            10.6.1. U.S.
            10.6.2. Canada
     10.7. Market Attractiveness Analysis 
            10.7.1. By Disease Indication 
            10.7.2. By Therapeutic Class 
            10.7.3. By Product Type 
            10.7.4. By Distribution Channels 
            10.7.5. By Country

11. Europe Ophthalmic Drugs Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
            11.1.3. Key Trends
     11.2. Market Value Forecast by Disease Indication, 2015–2025
            11.2.1. Dry Eye
            11.2.2. Glaucoma
            11.2.3. Infection/Inflammation
            11.2.4. Retinal Disorders
                     11.2.4.1. Wet AMD
                     11.2.4.2. Dry AMD
                     11.2.4.3. Diabetic Retinopathy
                     11.2.4.4. Others
            11.2.5. Allergy
            11.2.6. Uveitis
            11.2.7. Others
     11.3. Market Value Forecast by Therapeutic Class, 2015–2025
            11.3.1. Anti-inflammatory Drugs
                     11.3.1.1. NSAID
                     11.3.1.2. Steroids
            11.3.2. Anti-infective Drugs
                     11.3.2.1. Anti-fungal Drugs
                     11.3.2.2. Anti-bacterial Drugs
                     11.3.2.3. Others
            11.3.3. Anti-glaucoma Drugs
                     11.3.3.1. Alpha Agonist
                     11.3.3.2. Beta Blockers
                     11.3.3.3. Prostaglandin Analogs
                     11.3.3.4. Combined Medication
                     11.3.3.5. Others
            11.3.4. Anti-allergy Drugs
            11.3.5. Anti-VEGF Agents
            11.3.6. Others
     11.4. Market Value Forecast by Product Type, 2015–2025
            11.4.1. Prescription Drugs
            11.4.2. OTC Drugs
     11.5. Market Value Forecast by Distribution Channels, 2015–2025
            11.5.1. Hospital Pharmacies
            11.5.2. Online Pharmacies
            11.5.3. Independent Pharmacies & Drug Stores
     11.6. Market Value Forecast by Country, 2015–2025
            11.6.1. U.K.
            11.6.2. Germany
            11.6.3. France
            11.6.4. Italy
            11.6.5. Spain
            11.6.6. Russia
            11.6.7. Rest of Europe
     11.7. Market Attractiveness Analysis 
            11.7.1. By Disease Indication 
            11.7.2. By Therapeutic Class 
            11.7.3. By Product Type 
            11.7.4. By Distribution Channels 
            11.7.5. By Country

12. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
            12.1.3. Key Trends
     12.2. Market Value Forecast by Disease Indication, 2015–2025
            12.2.1. Dry Eye
            12.2.2. Glaucoma
            12.2.3. Infection/Inflammation
            12.2.4. Retinal Disorders
                     12.2.4.1. Wet AMD
                     12.2.4.2. Dry AMD
                     12.2.4.3. Diabetic Retinopathy
                     12.2.4.4. Others
            12.2.5. Allergy
            12.2.6. Uveitis
            12.2.7. Others
     12.3. Market Value Forecast by Therapeutic Class, 2015–2025
            12.3.1. Anti-inflammatory Drugs
                     12.3.1.1. NSAID
                     12.3.1.2. Steroids
            12.3.2. Anti-infective Drugs
                     12.3.2.1. Anti-fungal Drugs
                     12.3.2.2. Anti-bacterial Drugs
                     12.3.2.3. Others
            12.3.3. Anti-glaucoma Drugs
                     12.3.3.1. Alpha Agonist
                     12.3.3.2. Beta Blockers
                     12.3.3.3. Prostaglandin Analogs
                     12.3.3.4. Combined Medication
                     12.3.3.5. Others
            12.3.4. Anti-allergy Drugs
            12.3.5. Anti-VEGF Agents
            12.3.6. Others
     12.4. Market Value Forecast by Product Type, 2015–2025
            12.4.1. Prescription Drugs
            12.4.2. OTC Drugs
     12.5. Market Value Forecast by Distribution Channels, 2015–2025
            12.5.1. Hospital Pharmacies
            12.5.2. Online Pharmacies
            12.5.3. Independent Pharmacies & Drug Stores
     12.6. Market Value Forecast by Country, 2015–2025
            12.6.1. India
            12.6.2. China
            12.6.3. Japan
            12.6.4. Australia & New Zealand
            12.6.5. Rest of Asia Pacific
     12.7. Market Attractiveness Analysis 
            12.7.1. By Disease Indication 
            12.7.2. By Therapeutic Class 
            12.7.3. By Product Type 
            12.7.4. By Distribution Channels 
            12.7.5. By Country

13. Latin America Ophthalmic Drugs Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
            13.1.2. Policies and Regulations
            13.1.3. Key Trends
     13.2. Market Value Forecast by Disease Indication, 2015–2025
            13.2.1. Dry Eye
            13.2.2. Glaucoma
            13.2.3. Infection/Inflammation
            13.2.4. Retinal Disorders
                     13.2.4.1. Wet AMD
                     13.2.4.2. Dry AMD
                     13.2.4.3. Diabetic Retinopathy
                     13.2.4.4. Others
            13.2.5. Allergy
            13.2.6. Uveitis
            13.2.7. Others
     13.3. Market Value Forecast by Therapeutic Class, 2015–2025
            13.3.1. Anti-inflammatory Drugs
                     13.3.1.1. NSAID
                     13.3.1.2. Steroids
            13.3.2. Anti-infective Drugs
                     13.3.2.1. Anti-fungal Drugs
                     13.3.2.2. Anti-bacterial Drugs
                     13.3.2.3. Others
            13.3.3. Anti-glaucoma Drugs
                     13.3.3.1. Alpha Agonist
                     13.3.3.2. Beta Blockers
                     13.3.3.3. Prostaglandin Analogs
                     13.3.3.4. Combined Medication
                     13.3.3.5. Others
            13.3.4. Anti-allergy Drugs
            13.3.5. Anti-VEGF Agents
            13.3.6. Others
     13.4. Market Value Forecast by Product Type, 2015–2025
            13.4.1. Prescription Drugs
            13.4.2. OTC Drugs
     13.5. Market Value Forecast by Distribution Channels, 2015–2025
            13.5.1. Hospital Pharmacies
            13.5.2. Online Pharmacies
            13.5.3. Independent Pharmacies & Drug Stores
     13.6. Market Value Forecast by Country, 2015–2025
            13.6.1. Brazil
            13.6.2. Mexico
            13.6.3. Rest of Latin America
     13.7. Market Attractiveness Analysis 
            13.7.1. By Disease Indication 
            13.7.2. By Therapeutic Class 
            13.7.3. By Product Type 
            13.7.4. By Distribution Channels 
            13.7.5. By Country

14. Middle East and Africa Ophthalmic Drugs Market Analysis and Forecast
     14.1. Introduction
            14.1.1. Key Findings
            14.1.2. Policies and Regulations
            14.1.3. Key Trends
     14.2. Market Value Forecast by Disease Indication, 2015–2025
            14.2.1. Dry Eye
            14.2.2. Glaucoma
            14.2.3. Infection/Inflammation
            14.2.4. Retinal Disorders
                     14.2.4.1. Wet AMD
                     14.2.4.2. Dry AMD
                     14.2.4.3. Diabetic Retinopathy
                     14.2.4.4. Others
            14.2.5. Allergy
            14.2.6. Uveitis
            14.2.7. Others
     14.3. Market Value Forecast by Therapeutic Class, 2015–2025
            14.3.1. Anti-inflammatory Drugs
                     14.3.1.1. NSAID
                     14.3.1.2. Steroids
            14.3.2. Anti-infective Drugs
                     14.3.2.1. Anti-fungal Drugs
                     14.3.2.2. Anti-bacterial Drugs
                     14.3.2.3. Others
            14.3.3. Anti-glaucoma Drugs
                     14.3.3.1. Alpha Agonist
                     14.3.3.2. Beta Blockers
                     14.3.3.3. Prostaglandin Analogs
                     14.3.3.4. Combined Medication
                     14.3.3.5. Others
            14.3.4. Anti-allergy Drugs
            14.3.5. Anti-VEGF Agents
            14.3.6. Others
     14.4. Market Value Forecast by Product Type, 2015–2025
            14.4.1. Prescription Drugs
            14.4.2. OTC Drugs
     14.5. Market Value Forecast by Distribution Channels, 2015–2025
            14.5.1. Hospital Pharmacies
            14.5.2. Online Pharmacies
            14.5.3. Independent Pharmacies & Drug Stores
     14.6. Market Value Forecast by Country, 2015–2025
            14.6.1. South Africa
            14.6.2. GCC Countries
            14.6.3. Rest of Middle East and Africa
     14.7. Market Attractiveness Analysis 
            14.7.1. By Disease Indication 
            14.7.2. By Therapeutic Class 
            14.7.3. By Product Type 
            14.7.4. By Distribution Channels 
            14.7.5. By Country

15. Competition Landscape
     15.1. Market Player – Competition Matrix (By Tier and Size of companies)
     15.2. Market Share Analysis by Company (2016)
     15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            15.3.1. Aerie Pharmaceuticals, Inc. 
                     15.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.1.2 Financial Overview
                     15.3.1.3 Product Portfolio
                     15.3.1.4 SWOT Analysis
                     15.3.1.5 Strategic Overview
            15.3.2. ALLERGAN
                     15.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.2.2 Financial Overview
                     15.3.2.3 Product Portfolio
                     15.3.2.4 SWOT Analysis
                     15.3.2.5 Strategic Overview
            15.3.3. Valeant Pharmaceuticals International, Inc.
                     15.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.3.2 Financial Overview
                     15.3.3.3 Product Portfolio
                     15.3.3.4 SWOT Analysis
                     15.3.3.5 Strategic Overview
            15.3.4. Bayer AG 
                     15.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.4.2 Financial Overview
                     15.3.4.3 Product Portfolio
                     15.3.4.4 SWOT Analysis
                     15.3.4.5 Strategic Overview
            15.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
                     15.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.5.2 Financial Overview
                     15.3.5.3 Product Portfolio
                     15.3.5.4 SWOT Analysis
                     15.3.5.5 Strategic Overview
            15.3.6. Novartis AG 
                     15.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.6.2 Financial Overview
                     15.3.6.3 Product Portfolio
                     15.3.6.4 SWOT Analysis
                     15.3.6.5 Strategic Overview
            15.3.7. Pfizer Inc. 
                     15.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.7.2 Financial Overview
                     15.3.7.3 Product Portfolio
                     15.3.7.4 SWOT Analysis
                     15.3.7.5 Strategic Overview
            15.3.8. Regeneron Pharmaceuticals, Inc.
                     15.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.8.2 Financial Overview
                     15.3.8.3 Product Portfolio
                     15.3.8.4 SWOT Analysis
                     15.3.8.5 Strategic Overview 
            15.3.9. Santen Pharmaceutical Co., Ltd. 
                     15.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.9.2 Financial Overview
                     15.3.9.3 Product Portfolio
                     15.3.9.4 SWOT Analysis
                     15.3.9.5 Strategic Overview
            15.3.10. Shire
                     15.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.10.2 Financial Overview
                     15.3.10.3 Product Portfolio
                     15.3.10.4 SWOT Analysis
                     15.3.10.5 Strategic Overview
            15.3.11. Others

16. Key Take Aways

List of Figures

Figure 01: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Global Company Share: Anti-glaucoma Drugs, 2016
Figure 03: Global Causes of Blindness
Figure 04: U.S. - Causes of Blindness
Figure 05: Europe - Causes of Blindness
Figure 06: Japan Causes of Blindness
Figure 07: Global Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017–2025
Figure 08: Global Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
Figure 09: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Dry Eye, 2015–2025
Figure 10: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Glaucoma, 2015–2025
Figure 11: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Infection/Inflammation, 2015–2025
Figure 12: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Retinal Disorders, 2015–2025
Figure 13: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Uveitis, 2015–2025
Figure 14: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Allergy, 2015–2025
Figure 15: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Other Ophthalmic Diseases, 2015–2025
Figure 16: Global Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 17: Global Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
Figure 19: Global Ophthalmic Drugs Market, by Anti-infective Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 18: Global Ophthalmic Drugs Market, by Anti-inflammatory Drugs Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 20: Global Ophthalmic Drugs Market, by Anti-glaucoma Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 21: Global Ophthalmic Drugs Market, by Anti-VEGF Agents, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 22: Global Ophthalmic Drugs Market, by Anti-allergy Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 23: Global Ophthalmic Drugs Market, by Others Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 24: Global Ophthalmic Drugs Market Value Share, by Product Type, for 2017 and 2025
Figure 25: Global Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 26: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Prescription Drugs, 2015–2025
Figure 27: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by OTC Drugs, 2015–2025
Figure 28: Global Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2017 and 2025
Figure 29: Global Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 30: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Online Pharmacies, 2015–2025
Figure 31: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Hospital Pharmacies, 2015–2025
Figure 32: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Independent Pharmacies & Drug Stores, 2015–2025
Figure 33: Global Ophthalmic Drugs Market Value Share, by Region, for 2017 and 2025 
Figure 34: Global Ophthalmic Drugs Market Attractiveness, by Region, 2017–2025
Figure 35: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 36: North America Ophthalmic Drugs Market Attractiveness, by Country, 2017–2025
Figure 37: North America Ophthalmic Drugs Market Value Share, by Country, 2017 and 2025
Figure 38: North America Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2015–2025
Figure 39: North America Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
Figure 40: North America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
Figure 41: North America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 42: North America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 43: North America Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 44: North America Ophthalmic Drugs Market Value Share, by Distribution Channels, 2017 and 2025
Figure 45: North America Ophthalmic Drugs Market Attractiveness, by Distribution Channels , 2017–2025
Figure 46: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 47: Europe Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2017–2025
Figure 48: Europe Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2017 and 2025
Figure 49: Europe Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2015-2025
Figure 50: Europe Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
Figure 51: Europe Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
Figure 52: Europe Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 53: Europe Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 54: Europe Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 55: Europe Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 56: Europe Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 57: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 58: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 59: Asia Pacific Ophthalmic Drugs Market Value Share, by Country/Sub-region, for 2017 and 2025
Figure 60: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2015–2025
Figure 61: Asia Pacific Ophthalmic Drugs Market Value Share, by Disease Indication, for 2017 and 2025
Figure 62: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 63: Asia Pacific Ophthalmic Drugs Market Value Share, by Therapeutic Class, for 2017 and 2025
Figure 64: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Product Type, for 2017 and 2025
Figure 65: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 66: Asia Pacific Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2017 and 2025
Figure 67: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 68: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 69: Latin America Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 70: Latin America Ophthalmic Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
Figure 71: Latin America Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2015–2025
Figure 72: Latin America Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
Figure 73: Latin America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 74: Latin America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
Figure 75: Latin America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 76: Latin America Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 77: Latin America Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 78: Latin America Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 79: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 80: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2017–2025
Figure 81: Middle East & Africa Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2017 and 2025
Figure 82: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017–2025
Figure 83: Middle East & Africa Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
Figure 84: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2025
Figure 85: Middle East & Africa Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
Figure 86: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 87: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2025
Figure 88: Middle East & Africa Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017 and 2025
Figure 89: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 90: Global Ophthalmic Drugs Market Share, by Company, 2016

List of Tables

Table 01: Product Offering - Major Market Players
Table 02: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 03: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2015–2025
Table 04: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 05: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015–2025
Table 06: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015–2025
Table 07: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015–2025
Table 08: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 09: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 10: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 11: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 12: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 13: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2015–2025
Table 14: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 15: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015–2025
Table 16: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015–2025
Table 17: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015–2025
Table 18: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 19: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2015–2025
Table 20: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2015–2025
Table 21: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 22: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2015–2025
Table 23: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 24: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drug, 2015–2025
Table 25: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drug, 2015–2025
Table 26: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drug, 2015–2025
Table 27: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 28: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 29: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 30: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 31: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2015–2025
Table 32: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 33: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2015–2025
Table 34: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2015–2025
Table 35: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2015–2025
Table 36: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 37: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 38: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 39: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 40: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2015–2025
Table 41: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 42: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2015–2025
Table 43: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2015–2025
Table 44: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2015–2025
Table 45: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 46: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 47: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2015–2025
Table 48: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 49: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2015–2025
Table 50: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015–2025
Table 51: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015–2025
Table 52: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015–2025
Table 53: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015–2025
Table 54: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 55: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

Global Ophthalmic Drugs Market: Overview

Ophthalmic drugs is a growing market driven by rising prevalence of intraocular eye disorders mainly in elderly population like glaucoma, cataract, age-related macular degeneration, diabetic retinopathy, etc. Also, there is an increasing incidence of eye diseases globally such as dry eye, conjunctivitis, uveitis, and others, and the number of patients suffering from eye diseases is expected to grow exponentially during the forecast period. As a result of this increasing patient pool across the globe, major market players are increasing R&D investments to capture the significant commercial opportunity through innovations in treatment methods, and improvement in drug’s mechanism of action with novel biological agents.

The market overview section of the report comprises qualitative analysis of the overall ophthalmic drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the disease indications, therapeutic class, product type, and distribution channels, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics. The company share analysis has also been provided for global glaucoma drug market. The pipeline analysis of major as well as emerging market players has been given in the market overview section, along with the product comparison matrix of the major market players. The report also consists of a section depicting the major causes of blindness globally, as well as by regions.

Global Ophthalmic Drugs Market: Segmentation

The global ophthalmic drugs market is segmented in terms of disease indication, therapeutic class, product type, and distribution channels. The disease indication segment is further classified into dry eye, glaucoma, infection/inflammation, retinal disorders, allergy, uveitis, and others. The retinal disorders segment is further classified into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others. Among the disease indication segment, the retinal disorders segment accounted for the largest share of the global ophthalmic drugs market in 2016, owing to factors like exponentially rising patient pool demanding long-term treatment. However, the dry eye segment is expected to grow at a high CAGR during the forecast period, due to changing environmental conditions, pollutions, etc.

In terms of therapeutic class, global ophthalmic drugs market is divided into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, anti-allergy drugs, anti-VEGF agents, and others. The anti-inflammatory drugs segment is bi-furcated into nonsteroidal anti-inflammatory drugs, and steroids. The anti-infective drugs are further sub-segmented into anti-fungal drugs, anti-bacterial drugs, and others. The anti-glaucoma drugs segment is classified into alpha agonist, beta blockers, prostaglandin analogs, combined medication, and others. On the basis of product type, the market is segmented into prescription drugs and OTC drugs. Based on distribution channels, the global ophthalmic drugs market is segmented into hospital pharmacies, online pharmacies, and independent pharmacies & drug stores.

Geographically, the ophthalmic drugs market has been categorized into five regions namely: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2015 to 2025, in terms of disease indication, therapeutic class, product type, and distribution channels, along with the CAGR (%) for the forecast period 2017 to 2025.

Global Ophthalmic Drugs Market: Competitive Analysis

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global ophthalmic drugs market, in terms of percentage share in 2016 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the global ophthalmic drugs market such as Aerie Pharmaceuticals, Inc., ALLERGAN, Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc. (F. Hoffmann-La Roche Ltd.), Novartis AG , Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Shire among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

Global Ophthalmic Drugs Market is segmented as follows:

Global Ophthalmic Drugs Market, by Disease Indication

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation
  • Retinal Disorders
    • Wet Age-related Macular Degeneration
    • Dry Age-related Macular Degeneration
    • Diabetic Retinopathy
    • Others 
  • Allergy
  • Uveitis
  • Others

Global Ophthalmic Drugs Market, by Therapeutic Class

  • Anti-inflammatory Drugs
    • Nonsteroidal Anti-inflammatory Drugs
    • Steroids 
  • Anti-infective Drugs
    • Anti-fungal Drugs
    • Anti-bacterial Drugs
    • Others
  • Anti-glaucoma Drugs
    • Alpha Agonist
    • Beta Blockers
    • Prostaglandin Analogs
    • Combined Medication
    • Others 
  • Anti-allergy Drugs
  • Anti-VEGF Agents
  • Others

Global Ophthalmic Drugs Market, by Product Type

  • Prescription Drugs
  • Over-the-Counter Drugs

Global Ophthalmic Drugs Market, by Distribution Channel

  • Hospital Pharmacies
  • Online  Pharmacies
  • Independent Pharmacies & Drug Stores 

Global Ophthalmic Drugs Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa


 
 
Back To Top